SECURE Study: Combination Therapy with Cilostazol and Probucol for Atherosclerosis
Author Information
Author(s): Ko Young-Guk, Kim Byeong-Keuk, Lee Byoung Kwon, Kang Woong Chol, Choi Seung Hyuk, Kim Sang Wook, Lee Jong Ho, Lee Myoungsook, Honda Yasuhiro, Fitzerald Peter J, Shim Won-Heum
Primary Institution: Severance Cardiovascular Hospital, Yonsei University Health System
Hypothesis
Combination therapy with cilostazol and probucol is more effective in reducing plaque volume than cilostazol monotherapy.
Conclusion
The SECURE study aims to provide important insights into the effects of cilostazol and probucol combination therapy on atherosclerosis progression.
Supporting Evidence
- Probucol has been shown to prevent progression of atherosclerosis.
- Cilostazol has diverse antiatherogenic properties and reduces restenosis.
- Combination therapy has shown potential synergy in preventing atherosclerosis.
Takeaway
This study is testing if taking two heart medications together can help make heart arteries healthier than just taking one.
Methodology
A double-blind, randomized, controlled, multicenter clinical trial using intravascular ultrasound and Virtual Histology to assess plaque volume and composition.
Potential Biases
Potential bias in patient selection and data collection due to the nature of the study design.
Limitations
Relatively small sample size and short follow-up duration for IVUS study.
Participant Demographics
Patients over 20 years of age with significant coronary artery stenosis requiring PCI.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website